N. Devoogdt

Nick Devoogdt, Tony Lahoutte, Serge Muyldermans, 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy.

Liesbet Lagae, Gustaaf Borghs, Nick Devoogdt, 2011, ACS nano.

Development and Characterization of Nanobodies Targeting the Kupffer Cell

S. Muyldermans, N. Devoogdt, S. Schoonooghe, 2021, Frontiers in Immunology.

The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm

N. Devoogdt, Q. Lecocq, K. Breckpot, 2020, International journal of molecular sciences.

Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours.

M. Defrise, N. Devoogdt, P. Mollard, 2019, Journal of controlled release : official journal of the Controlled Release Society.

Targeting of vascular cell adhesion molecule-1 by 18F-labelled nanobodies for PET/CT imaging of inflamed atherosclerotic plaques.

C. Vanhove, N. Devoogdt, A. Broisat, 2016, European heart journal cardiovascular Imaging.

Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments: a versatile strategy for multiple molecular imaging modalities.

C. Vanhove, S. Muyldermans, J. Steyaert, 2016, Contrast media & molecular imaging.

Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging.

S. Muyldermans, N. Devoogdt, Sam Massa, 2014, Bioconjugate chemistry.

Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice.

C. Vanhove, S. Muyldermans, A. Bossuyt, 2011, Contrast media & molecular imaging.

Monitoring liver macrophages using nanobodies targeting Vsig4: concanavalin A induced acute hepatitis as paradigm.

S. Muyldermans, P. De Baetselier, N. Devoogdt, 2015, Immunobiology.

The Design and Preclinical Evaluation of a Single-Label Bimodal Nanobody Tracer for Image-Guided Surgery

N. Devoogdt, S. Hernot, F. V. van Leeuwen, 2021, Biomolecules.

Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators.

S. Muyldermans, A. Aerts, S. Baatout, 2012, Contrast media & molecular imaging.

Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation

C. Vanhove, N. Devoogdt, Q. Lecocq, 2020, Biomolecules.

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy

N. Devoogdt, Q. Lecocq, K. Breckpot, 2018, Theranostics.

Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production

N. Devoogdt, Q. Lecocq, K. Thielemans, 2019, Vaccines.

Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells

Y. Saeys, B. Lambrecht, P. De Baetselier, 2016, Nature Communications.

Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al18F-RESCA method

G. Bormans, N. Devoogdt, C. Xavier, 2018, Nature Protocols.

Al18F-Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging

G. Bormans, N. Devoogdt, A. Verbruggen, 2017, Theranostics.

Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies

S. Muyldermans, U. Wernery, N. Devoogdt, 2014, Leukemia.

Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells

P. De Baetselier, N. Devoogdt, L. Brys, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[18F]Fluoronicotinate Resulting in High Tumor-to-Kidney Ratios.

N. Devoogdt, M. Zalutsky, Zhengyuan Zhou, 2018, Molecular pharmaceutics.

A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma

F. Baron, N. Devoogdt, M. Dumoulin, 2021, Journal of Hematology & Oncology.

Newer Bioconjugation Methods

N. Devoogdt, A. Krasniqi, C. Xavier, 2021, Molecular Imaging.

Evaluation of Antiatherogenic Properties of Ezetimibe Using 3H-Labeled Low-Density-Lipoprotein Cholesterol and 99mTc-cAbVCAM1–5 SPECT in ApoE−/− Mice Fed the Paigen Diet

Laurent S Dumas, P. Perret, T. Sulpice, 2017, The Journal of Nuclear Medicine.

In Vitro Analysis and In Vivo Tumor Targeting of a Humanized, Grafted Nanobody in Mice Using Pinhole SPECT/Micro-CT

S. Muyldermans, P. De Baetselier, A. Bossuyt, 2010, Journal of Nuclear Medicine.

Radiotheranostic Agents in Hematological Malignancies

N. Withofs, A. Karlström, N. Devoogdt, 2022, Frontiers in Immunology.

Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.

S. Muyldermans, N. Devoogdt, Shahriyar Abdoli, 2014, Contrast media & molecular imaging.

Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma

C. Vanhove, T. Gevaert, N. Devoogdt, 2016, The Journal of Nuclear Medicine.

Improved Detection of Molecular Markers of Atherosclerotic Plaques Using Sub-Millimeter PET Imaging

C. Vanhove, G. Bormans, N. Devoogdt, 2020, Molecules.

Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis

Z. Fayad, Jason S. Lewis, N. Karakatsanis, 2018, JACC. Cardiovascular imaging.

Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade

N. Devoogdt, Y. De Vlaeminck, Q. Lecocq, 2021, The Journal of Nuclear Medicine.

Nanobody nuclear imaging allows noninvasive quantification of LAG- 3 expression by tumor-infiltrating leukocytes and predicts response of immune checkpoint blockade

N. Devoogdt, Q. Lecocq, K. Thielemans, 2021 .

Preclinical Targeted α- and β−-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies

A. Windhorst, N. Devoogdt, Q. Lecocq, 2020, Cancers.

Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide–Cysteine Chemistry

N. Devoogdt, Q. Lecocq, K. Breckpot, 2021, Pharmaceuticals.

Bioconjugation

N. Devoogdt, Sam Massa, 2019, Methods in Molecular Biology.

Specificity Evaluation and Disease Monitoring in Arthritis Imaging with Complement Receptor of the Ig superfamily targeting Nanobodies

S. Muyldermans, P. De Baetselier, H. Perlman, 2016, Scientific Reports.

Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.

N. Devoogdt, M. Zalutsky, S. Chitneni, 2018, Bioorganic & medicinal chemistry.

Cytoplasmic versus periplasmic expression of site-specifically and bioorthogonally functionalized nanobodies using expressed protein ligation.

P. Adriaensens, S. Muyldermans, N. Devoogdt, 2017, Protein expression and purification.

Molecular Imaging with Macrophage CRIg-Targeting Nanobodies for Early and Preclinical Diagnosis in a Mouse Model of Rheumatoid Arthritis

S. Muyldermans, P. De Baetselier, L. Bouwens, 2014, The Journal of Nuclear Medicine.

Site-Specific Radioactive Labeling of Nanobodies.

S. Muyldermans, N. Devoogdt, Sam Massa, 2018, Methods in molecular biology.

Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody

S. Muyldermans, A. Aerts, S. Baatout, 2014, Theranostics.

Radiometal-labeled anti-VCAM-1 nanobodies as molecular tracers for atherosclerosis – impact of radiochemistry on pharmacokinetics

Laurent S Dumas, S. Dübel, Andrea L J Marschall, 2018, Biological chemistry.

Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent

N. Devoogdt, Q. Lecocq, S. Schoonooghe, 2019, Cancers.

Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer

N. Devoogdt, Y. De Vlaeminck, Q. Lecocq, 2021, EJNMMI Research.

Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use

N. Devoogdt, Y. De Vlaeminck, Q. Lecocq, 2019, Biomolecules.

Vrije Universiteit Brussel Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use Lecocq,

N. Devoogdt, Q. Lecocq, Sam Massa, 2019 .

Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade

M. Verdonck, A. Van Parys, N. Devoogdt, 2021, Molecular therapy. Methods & clinical development.

Camelid reporter gene imaging: a generic method for in vivo cell tracking

N. Devoogdt, T. Lahoutte, T. Bos, 2014, EJNMMI Research.

Molecular Imaging with Kupffer Cell-Targeting Nanobodies for Diagnosis and Prognosis in Mouse Models of Liver Pathogenesis

S. Muyldermans, P. De Baetselier, N. Devoogdt, 2017, Molecular Imaging and Biology.

Site-Selective Functionalization of Nanobodies Using Intein-Mediated Protein Ligation for Innovative Bioconjugation.

P. Adriaensens, S. Muyldermans, N. Devoogdt, 2019, Methods in molecular biology.

Development and Validation of a Small Single-domain Antibody That Effectively Inhibits Matrix Metalloproteinase 8.

Y. Saeys, L. Arckens, R. Vandenbroucke, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation

I. Balyasnikova, N. Devoogdt, M. Zalutsky, 2017, Molecular Imaging and Biology.

Non-canonical roles of connexins.

S. Muyldermans, M. Vinken, N. Devoogdt, 2020, Progress in biophysics and molecular biology.

The regulated expression of an intrabody produces a mutant phenotype in Drosophila

S. Muyldermans, P. De Baetselier, A. Ghysen, 1998, FEBS letters.

Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors.

N. Devoogdt, Evangelia Bolli, K. Movahedi, 2019, Journal of controlled release : official journal of the Controlled Release Society.

Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages

N. Devoogdt, Evangelia Bolli, K. Movahedi, 2019, Molecular Imaging and Biology.

single-domain antibody fragments.

G. Bormans, N. Devoogdt, S. Schoonooghe, 2015 .

An Efficient Method for Labeling Single Domain Antibody Fragments with 18F Using Tetrazine- Trans-Cyclooctene Ligation and a Renal Brush Border Enzyme-Cleavable Linker.

N. Devoogdt, M. Zalutsky, Zhengyuan Zhou, 2018, Bioconjugate chemistry.

Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma

J. Tavernier, S. Muyldermans, N. Devoogdt, 2017, Molecular Cancer Therapeutics.

A nanobody-based nuclear imaging tracer targeting dipeptidyl peptidase 6 to determine the mass of human beta cell grafts in mice

P. Marchetti, F. Pattou, D. Eizirik, 2019, Diabetologia.

Monday, 27 August 2012

V. V. Ivanenko, E. A. Medvedeva, Michail I. Papafaklis, 2012 .

Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20.

S. Muyldermans, N. Devoogdt, A. Krasniqi, 2018, New biotechnology.

Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.

N. Devoogdt, M. Zalutsky, T. Lahoutte, 2013, Nuclear medicine and biology.

Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha

S. Muyldermans, N. Devoogdt, K. Movahedi, 2021, Frontiers in Immunology.

Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33

S. Muyldermans, N. Devoogdt, Yann G. J. Sterckx, 2020, International journal of molecular sciences.

Nanobodies and their potential applications.

S. Muyldermans, N. Devoogdt, G. Hassanzadeh-Ghassabeh, 2013, Nanomedicine.

The antigen‐binding moiety in the driver's seat of CARs

N. Devoogdt, K. Breckpot, K. De Veirman, 2021, Medicinal research reviews.

Immunogenicity Risk Profile of Nanobodies

S. Muyldermans, N. Devoogdt, K. Breckpot, 2021, Frontiers in Immunology.

In Vivo Assessment of VCAM-1 Expression by SPECT/CT Imaging in Mice Models of Human Triple Negative Breast Cancer

Laurent S Dumas, P. Perret, G. Pagès, 2019, Cancers.

Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers

Marleen Keyaerts, Nick Devoogdt, David Escors, 2017, Oncotarget.

Classical and alternative activation of macrophages: different pathways of macrophage-mediated tumor promotion

N. Devoogdt, L. Brys, H. Revets, 2008 .

Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases

N. Devoogdt, T. Lahoutte, J. Puttemans, 2019, Pharmaceutics.

Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.

S. Muyldermans, N. Devoogdt, Gholamreza Hassanzadeh, 2017, Current pharmaceutical design.

Increased Expression of Adherens Junction Components in Mouse Liver following Bile Duct Ligation

S. Muyldermans, M. Vinken, N. Devoogdt, 2019, Biomolecules.

AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model

W. Derave, N. Devoogdt, J. Gettemans, 2017, Human molecular genetics.

SPECT Imaging of Joint Inflammation with Nanobodies Targeting the Macrophage Mannose Receptor in a Mouse Model for Rheumatoid Arthritis

P. De Baetselier, N. Devoogdt, S. Schoonooghe, 2013, The Journal of Nuclear Medicine.

The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy

N. Devoogdt, T. Lahoutte, F. Bruchertseifer, 2021, Molecular Cancer Therapeutics.

Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor

S. Muyldermans, M. Vinken, N. Devoogdt, 2021, Biomolecules.

Ultrasound Molecular Imaging of Atherosclerosis With Nanobodies: Translatable Microbubble Targeting Murine and Human VCAM (Vascular Cell Adhesion Molecule) 1.

N. Devoogdt, B. Kaufmann, A. Broisat, 2019, Arteriosclerosis, thrombosis, and vascular biology.

Nanobody-coupled microbubbles as novel molecular tracer.

Jakub Toczek, S. Muyldermans, N. Devoogdt, 2012, Journal of controlled release : official journal of the Controlled Release Society.

A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells

R. Scharfmann, S. Muyldermans, P. Marchetti, 2017, Scientific Reports.

Secretory Leukocyte Protease Inhibitor in Cancer Development

N. Devoogdt, H. Revets, P. Baetselier, 2004, Annals of the New York Academy of Sciences.

Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy

A. Windhorst, K. Brindle, M. Essler, 2021, Pharmaceuticals.

The Tumor-Promoting Effect of TNF-α Involves the Induction of Secretory Leukocyte Protease Inhibitor1

P. De Baetselier, N. Devoogdt, H. Revets, 2006, The Journal of Immunology.

Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages.

P. De Baetselier, L. Bouwens, N. Devoogdt, 2012, Cancer research.

(18)F-nanobody for PET imaging of HER2 overexpressing tumors.

Nick Devoogdt, Tony Lahoutte, Ilse Vaneycken, 2016, Nuclear medicine and biology.

The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells.

E. Kohn, E. Alejandro, N. Devoogdt, 2007, Carcinogenesis.

Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target

S. Muyldermans, N. Devoogdt, T. Lahoutte, 2013, Expert opinion on biological therapy.

Site-specific labeling of his-tagged Nanobodies with ⁹⁹mTc: a practical guide.

N. Devoogdt, Sam Massa, S. Hernot, 2012, Methods in molecular biology.

Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer

S. Muyldermans, N. Devoogdt, V. Caveliers, 2014, Expert opinion on drug delivery.

Effect of Dye and Conjugation Chemistry on the Biodistribution Profile of Near-Infrared-Labeled Nanobodies as Tracers for Image-Guided Surgery.

N. Devoogdt, Sam Massa, S. Hernot, 2017, Molecular pharmaceutics.

Nanobodies for the Early Detection of Ovarian Cancer

P. Adriaensens, S. Muyldermans, N. Devoogdt, 2022, International journal of molecular sciences.

131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment

N. Devoogdt, M. Zalutsky, Sam Massa, 2017, Clinical Cancer Research.

Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients

A. Windhorst, N. Devoogdt, F. Duhoux, 2020, The Journal of Nuclear Medicine.

Reshaping Nanobodies for affinity purification on protein A.

S. Muyldermans, N. Devoogdt, C. Vincke, 2020, New biotechnology.

Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer

Marleen Keyaerts, Nick Devoogdt, Tony Lahoutte, 2013, The Journal of Nuclear Medicine.

Evaluation of [99mTc]Radiolabeled Macrophage Mannose Receptor-Specific Nanobodies for Targeting of Atherosclerotic Lesions in Mice

N. Devoogdt, S. Hernot, T. Lahoutte, 2018, Molecular Imaging and Biology.

Mechanisms Underlying Connexin Hemichannel Activation in Disease

S. Muyldermans, M. Vinken, N. Devoogdt, 2021, International journal of molecular sciences.

PET Imaging of Macrophage Mannose Receptor–Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments

Guy Bormans, Nick Devoogdt, Tony Lahoutte, 2015, The Journal of Nuclear Medicine.

99mTc-cAbVCAM1-5 Imaging Is a Sensitive and Reproducible Tool for the Detection of Inflamed Atherosclerotic Lesions in Mice

Gilles Barone-Rochette, Daniel Fagret, Catherine Ghezzi, 2014, The Journal of Nuclear Medicine.

An affinity-enhanced, broadly neutralizing heavy chain–only antibody protects against SARS-CoV-2 infection in animal models

P. Maes, N. Callewaert, B. Weynand, 2021, Science Translational Medicine.

Drug development of an affinity enhanced, broadly neutralizing heavy chain-only antibody that restricts SARS-CoV-2 in rodents

P. Maes, N. Callewaert, B. Weynand, 2021, bioRxiv.

Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy

N. Devoogdt, T. Ertveldt, P. Covens, 2023, Pharmaceutics.

Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment

N. Devoogdt, Q. Lecocq, C. Goyvaerts, 2023, The Journal of Nuclear Medicine.

Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177–Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model

N. Devoogdt, Y. De Vlaeminck, Q. Lecocq, 2022, Molecular cancer therapeutics.

Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology

Fredrik Y Frejd, V. Tolmachev, F. Frejd, 2018, The Journal of Nuclear Medicine.

Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle

Marleen Keyaerts, Nick Devoogdt, Tony Lahoutte, 2016, Expert opinion on biological therapy.

Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling

H. Lyerly, N. Devoogdt, M. Zalutsky, 2014, The Journal of Nuclear Medicine.

Characterization and site-specific bio-functionalization of nanobodies for the early detection of ovarian cancer biomarkers

P. Adriaensens, S. Muyldermans, N. Devoogdt, 2019 .

Overexpression of protease inhibitor‐dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo

E. Kohn, N. Devoogdt, N. Rasool, 2009, Cancer science.

Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided Surgery

N. Devoogdt, S. Hernot, P. Debie, 2019, Antibodies.

Direct Immobilization of Engineered Nanobodies on Gold Sensors

P. Adriaensens, S. Muyldermans, M. Alexander, 2021, ACS applied materials & interfaces.

Emerging site-specific bioconjugation strategies for radioimmunotracer development

S. Muyldermans, N. Devoogdt, Sam Massa, 2016, Expert opinion on drug delivery.

Correlation Between Epidermal Growth Factor Receptor-Specific Nanobody Uptake and Tumor Burden: A Tool for Noninvasive Monitoring of Tumor Response to Therapy

C. Vanhove, S. Muyldermans, N. Devoogdt, 2011, Molecular Imaging and Biology.

Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al18F-RESCA method

G. Bormans, N. Devoogdt, C. Xavier, 2018, Nature Protocols.

Improved Debulking of Peritoneal Tumor Implants by Near-Infrared Fluorescent Nanobody Image Guidance in an Experimental Mouse Model

N. Devoogdt, S. Hernot, T. Lahoutte, 2018, Molecular Imaging and Biology.

Rational Design of Nanobody80 Loop Peptidomimetics: Towards Biased β2 Adrenergic Receptor Ligands.

Samuel L. C. Moors, E. Pardon, J. Steyaert, 2017, Chemistry.

Surface display of a single-domain antibody library on Gram-positive bacteria

S. Muyldermans, U. Wernery, S. Ståhl, 2013, Cellular and Molecular Life Sciences.

A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells

R. Scharfmann, S. Muyldermans, S. Goldman, 2017, Scientific Reports.

Non-Invasive Imaging of Amyloid Deposits in a Mouse Model of AGel Using 99mTc-Modified Nanobodies and SPECT/CT

N. Devoogdt, J. Gettemans, T. Lahoutte, 2016, Molecular Imaging and Biology.

A few good reasons to use nanobodies for cancer treatment

N. Devoogdt, J. V. Van Ginderachter, B. Stijlemans, 2023, European journal of immunology.

Phase I Trial of 131 I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients

A. Windhorst, N. Devoogdt, F. Duhoux, 2021 .

Molecular imaging of liver inflammation using an anti-VCAM-1 nanobody

I. Leclercq, P. Perret, T. Sulpice, 2023, Nature Communications.

Preclinical 131 I-labeled Anti-HER 2 Camelid sdAb as a Theranostic Tool in Cancer Treatment

N. Devoogdt, M. Zalutsky, Sam Massa, 2017 .

Current status and future expectations of nanobodies in oncology trials

N. Devoogdt, J. V. Van Ginderachter, G. Raes, 2023, Expert opinion on investigational drugs.

Safety assessment of fluorescently labeled anti-EGFR Nanobodies in healthy dogs

N. Devoogdt, S. Hernot, H. de Rooster, 2023, Frontiers in pharmacology.

Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer

S. Muyldermans, U. Wernery, N. Devoogdt, 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Evaluation of [99mTc]Radiolabeled Macrophage Mannose Receptor-Specific Nanobodies for Targeting of Atherosclerotic Lesions in Mice

N. Devoogdt, S. Hernot, T. Lahoutte, 2018, Molecular Imaging and Biology.

Nanobody-based pannexin1 channel inhibitors reduce inflammation in acute liver injury

N. Devoogdt, Timo W. M. De Groof, Raf Van Campenhout, 2023, Journal of Nanobiotechnology.

SPECT Imaging of Joint Inflammation with Nanobodies Targeting the Macrophage Mannose Receptor in a Mouse Model for Rheumatoid Arthritis

P. De Baetselier, N. Devoogdt, S. Schoonooghe, 2013, The Journal of Nuclear Medicine.

Nanobody nuclear imaging allows noninvasive quantification of LAG- 3 expression by tumor-infiltrating leukocytes and predicts response of immune checkpoint blockade

N. Devoogdt, Q. Lecocq, K. Thielemans, 2021 .

Molecular imaging using Nanobodies: a case study.

Nick Devoogdt, Tony Lahoutte, Ilse Vaneycken, 2012, Methods in molecular biology.

Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT

N. Devoogdt, G. Raes, T. Ertveldt, 2023, Frontiers in immunology.

Targeted radionuclide therapy with low and high-dose Lutetium-177 labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model

N. Devoogdt, Q. Lecocq, C. Goyvaerts, 2022 .

Improved Debulking of Peritoneal Tumor Implants by Near-Infrared Fluorescent Nanobody Image Guidance in an Experimental Mouse Model

N. Devoogdt, S. Hernot, T. Lahoutte, 2018, Molecular Imaging and Biology.

Molecular Imaging with Macrophage CRIg-Targeting Nanobodies for Early and Preclinical Diagnosis in a Mouse Model of Rheumatoid Arthritis

S. Muyldermans, P. De Baetselier, L. Bouwens, 2014, The Journal of Nuclear Medicine.

Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma

J. Tavernier, S. Muyldermans, N. Devoogdt, 2017, Molecular Cancer Therapeutics.

Cytoplasmic versus periplasmic expression of site-specifically and bioorthogonally functionalized nanobodies using expressed protein ligation.

P. Adriaensens, S. Muyldermans, N. Devoogdt, 2017, Protein expression and purification.

Nanobodies as Tools for In Vivo Imaging of Specific Immune Cell Types

S. Muyldermans, P. De Baetselier, N. Devoogdt, 2010, Journal of Nuclear Medicine.

Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8+ T cell and iNKT cell activating mRNA vaccine

N. Devoogdt, Y. De Vlaeminck, C. Goyvaerts, 2023, Theranostics.

Promising Diagnostic and Therapeutic Approaches Based on VHHs for Cancer Management

N. Devoogdt, A. Yaromina, Philippe Lambin, 2024, Cancers.

Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties

N. Devoogdt, Y. De Vlaeminck, K. De Veirman, 2024, International journal of molecular sciences.

Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization

N. Devoogdt, Y. De Vlaeminck, Q. Lecocq, 2024, Frontiers in immunology.

Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.

N. Devoogdt, M. Zalutsky, T. Lahoutte, 2013, Nuclear medicine and biology.

Phase II Trial Assessing the Repeatability and Tumor Uptake of [68Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma

N. Devoogdt, V. Caveliers, T. Lahoutte, 2024, The Journal of Nuclear Medicine.

Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling

N. Devoogdt, M. Zalutsky, T. Lahoutte, 2014, The Journal of Nuclear Medicine.

Immunogenicity Risk Pro le of Nanobodies

S. Muyldermans, N. Devoogdt, A. Abbady, 2021 .

Generation and Characterization of Novel Pan‐Cancer Anti‐uPAR Fluorescent Nanobodies as Tools for Image‐Guided Surgery

N. Devoogdt, P. Debie, J. Puttemans, 2024, Advanced science.

Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α

N. Devoogdt, Sam Massa, J. V. Van Ginderachter, 2023, The Journal of Nuclear Medicine.

Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages

N. Devoogdt, Evangelia Bolli, K. Movahedi, 2019, Molecular Imaging and Biology.

Sustained release of a human pd-l1 single-domain antibody using peptide-based hydrogels.

N. Devoogdt, V. Caveliers, A. Madder, 2024, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.